Diane E. Webster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diane E. Webster has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alison E. Campbell
Department of Microbiology, Monash University, Clayton, Australia
1 shared publication - Charles Ma
Department of Microbiology, Monash University, Clayton Vic 3800, Australia
1 shared publication - Lina Wang
Department of Microbiology, Monash University, Clayton, Australia
1 shared publication - Merlin Christopher Thomas
Monash University
1 shared publication - Ross L. Coppel
Department of Microbiology, Monash University, Clayton, Australia
1 shared publication
Latest Publications
- 1 March 2012
- Published by Elsevier in Biotechnology Advances
- Vol. 30 (2) , 410-418
Post-translational modification of plant-made foreign proteins; glycosylation and beyond
- 1 March 2012
- Published by Elsevier in Biotechnology Advances
- Vol. 30 (2) , 410-418
Post-translational modification of plant-made foreign proteins; glycosylation and beyond
- 15 December 2011
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 94 (1) , 151-161
Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1
Development of a safe, effective and affordable malaria vaccine is central to global disease control efforts. One of the most highly regarded proteins for inclusion in an asexual blood stage subunit vaccine is the 19-kDa C-terminal fragment of merozoite surface protein 1 (MSP119). As production of vaccine antigens in plants can potentially overcome cost and delivery hurdles, we set out to produce MSP119 in plants, characterise the protein and test its immunogenicity using a mouse model. Plasmodium yoelii MSP119 (PyMSP119) was produced in Nicotiana benthamiana using the MagnICON® deconstructed TMV-based viral vector. PyMSP119 yield of at least 23% total soluble protein (TSP;3–4 mg/g Fwt) were achieved using a codon-optimised construct that was targeted to the apoplast. Freeze-dried leaf powder contained at least 20 mg PyMSP119 per gram dry weight and the protein retained immunogenicity in this form for more than 2 years. Characterisation studies, including SDS-PAGE, mass spectrometry and circular dichroism, indicated that the plant-expressed PyMSP119 was similar to its Escherichia coli- and Saccharomyces cerevisiae-expressed counterparts. Purified plant-made PyMSP119 induced strong immune responses following intraperitoneal immunisation, although titres were lower than those induced by an equivalent dose of purified E. coli-expressed PyMSP119. The reason for this is uncertain but may be due to differences in the oligomerisation profile of the vaccines. The plant-made PyMSP119 vaccine was also found to be orally immunogenic when delivered alone or following immunisation with a PyMSP119 DNA vaccine. This study adds to an increasing body of research supporting the feasibility of plants as both a factory for the production of malaria antigens, and as a safe and affordable platform for oral delivery of a temperature-stable malaria vaccine.
- 15 December 2011
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 94 (1) , 151-161
Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1
Development of a safe, effective and affordable malaria vaccine is central to global disease control efforts. One of the most highly regarded proteins for inclusion in an asexual blood stage subunit vaccine is the 19-kDa C-terminal fragment of merozoite surface protein 1 (MSP119). As production of vaccine antigens in plants can potentially overcome cost and delivery hurdles, we set out to produce MSP119 in plants, characterise the protein and test its immunogenicity using a mouse model. Plasmodium yoelii MSP119 (PyMSP119) was produced in Nicotiana benthamiana using the MagnICON® deconstructed TMV-based viral vector. PyMSP119 yield of at least 23% total soluble protein (TSP;3–4 mg/g Fwt) were achieved using a codon-optimised construct that was targeted to the apoplast. Freeze-dried leaf powder contained at least 20 mg PyMSP119 per gram dry weight and the protein retained immunogenicity in this form for more than 2 years. Characterisation studies, including SDS-PAGE, mass spectrometry and circular dichroism, indicated that the plant-expressed PyMSP119 was similar to its Escherichia coli- and Saccharomyces cerevisiae-expressed counterparts. Purified plant-made PyMSP119 induced strong immune responses following intraperitoneal immunisation, although titres were lower than those induced by an equivalent dose of purified E. coli-expressed PyMSP119. The reason for this is uncertain but may be due to differences in the oligomerisation profile of the vaccines. The plant-made PyMSP119 vaccine was also found to be orally immunogenic when delivered alone or following immunisation with a PyMSP119 DNA vaccine. This study adds to an increasing body of research supporting the feasibility of plants as both a factory for the production of malaria antigens, and as a safe and affordable platform for oral delivery of a temperature-stable malaria vaccine.